Evidence-Based Complementary and Alternative Medicine / 2019 / Article / Tab 2

Review Article

An Overview of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Formula Granules

Table 2

Comparison of the cure rate between CHM formula granules and placebo.

Study IDTreatmentPlaceboP value
n/N%n/N%

HBV carrier: HBV DNA negative after 48-week treatment
He JS 20121/1740.570/930.000.77
Li HZ 20123/1911.570/940.000.35
Ni W 20153/407.500/200.000.41
Xing YF 20123/1911.571/1870.530.38
Meta-analysis RR and 95% CI: 2.97 ; I2 = 0%

HBV carrier: HBeAg negative after 48-week treatment
He JS 201211/1746.323/933.230.29
Li HZ 20127/1913.663/943.190.84
Ni W 20155/4012.501/205.000.38
Zheng YJ 20126/5610.712/573.510.15
Meta-analysis RR and 95% CI: 1.99 ; I2 = 0%

HBV recrudescence: HBV DNA negative after 48-week treatment
Zhang ZE 20139/2339.131/234.350.02

HBV recrudescence: HBeAg negative after 48-week treatment
Zhang ZE 20137/2330.432/238.700.08

Chronic hepatitis C: HCV RNA negative after 48-weektreatment and 24-week follow-up
Zhao L 2014 (HCV-1b)4/449.090/510.000.11
Zhao L 2014 (HCV-other)6/1442.861/156.670.04
Zhao L 2014-110/6016.673/684.410.03
Meta-analysis RR and 95% CI: 6.26 ; I2 = 0%

Non-alcoholic fatty liver disease: Normal ALT and B-ultrasound after 12-week treatment
Cheng Y 201719/4047.5010/4025.000.04

Depression: Reduction in Edinburgh Postnatal Depression Scale (EPDS)≥80
Xu F 2013-113/5026.004/508.000.02
Xu F 201314/4531.116/4513.330.05

Fever: Normal temperature and resolution of cold symptoms
Cheng Y 201627/4165.8518/4045.000.06
Xie JH 201729/4860.4217/4835.420.02
Meta-analysis RR and 95% CI: 2.58 ; I2 = 0%

Migraine: Resolution of symptoms after 12-week treatment and at 2-month follow-up
Xu YL 20114/2416.670/240.000.12

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.